



**Vivimed**

Date: 13/02/2016

To

BSE Limited  
Listing Department  
P.J.Towers, Dalal Street,  
Mumbai – 400001

**BSE - Scripe Code : 532660**

National Stock Exchange of India Ltd  
Listing Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra(E), Mumbai – 400051

**NSE- Symbol: VIVIMEDLAB**

Dear Sir/Madam

**Sub: Outcome of the Meeting of the Board of Directors of the Company – reg**

The Board of Directors of the Company at its meeting held on 13<sup>th</sup> February, 2016, inter alia, have approved/resolved/taken note of the following:

1. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, considered and approved the submission of the Un audited Financial Results (Standalone & Consolidated) for the Quarter & Nine months ended December 31,2015 attached herewith;
2. The Board took note of Auditor's Limited Review Report on the un Audited Financial Statements of the Company for the Quarter & Nine months ended December 31,2015

You are requested to take note of the above.

Yours faithfully

For VIVIMED LABS LTD

  
**SANTOSH VARALWAR**  
**MANAGING DIRECTOR & CEO**



VIVIMED LABS LIMITED  
STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2015

₹ in Lacs

Sl. No.	Particulars	Quarter Ended			Nine Months Ended		Previous Year ended 31.03.2015	
		31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014		
1	Income From Operations	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
	(a) Net Sales / Income from Operations (Net of Excise Duty)	32,991.12	33,702.81	34,370.89	99,846.77	102,388.40	138,009.91	
	(b) Other Operating Income	196.77	452.30	98.62	792.47	774.11	586.57	
	<b>Total Income From Operations (Net)</b>	<b>33,187.89</b>	<b>34,154.91</b>	<b>34,469.51</b>	<b>100,639.24</b>	<b>103,112.50</b>	<b>138,596.49</b>	
	a. Cost of Raw Materials Consumed	15,023.74	15,448.89	17,292.61	45,845.33	52,772.58	69,931.61	
	b. Purchase of Stock in Trade	43.70	497.50	(1,516.56)	(12.72)	(4,883.41)	(5,309.20)	
	c. Changes in Inventories of Finished Goods, Work-in-Progress and Stock in Trade	3,825.02	3,776.21	4,780.18	12,144.26	13,721.67	18,442.79	
	d. Depreciation and Amortisation Expenses	1,545.04	1,638.86	1,843.10	4,662.28	5,147.06	6,617.76	
	e. Depreciation and Amortisation Expenses	8,169.44	8,114.71	7,886.57	23,496.57	24,301.97	33,256.12	
	f. Other Expenditure	28,606.94	29,476.17	30,285.90	86,135.72	91,059.87	122,939.08	
2	<b>Total Expenses</b>	<b>4,580.95</b>	<b>4,678.74</b>	<b>4,183.61</b>	<b>14,503.52</b>	<b>12,052.63</b>	<b>15,657.41</b>	
3	<b>Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)</b>	<b>28,606.94</b>	<b>29,476.17</b>	<b>30,285.90</b>	<b>86,135.72</b>	<b>91,059.87</b>	<b>122,939.08</b>	
4	Other Income	-	-	-	-	-	-	
5	<b>Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)</b>	<b>4,580.95</b>	<b>4,678.74</b>	<b>4,183.61</b>	<b>14,503.52</b>	<b>12,052.63</b>	<b>15,657.41</b>	
6	Finance Costs	1,921.72	1,879.61	1,937.23	5,705.83	5,933.68	7,903.68	
7	<b>Profit / (Loss) from Ordinary Activities, after Finance Costs but before exceptional items (5 - 6)</b>	<b>2,659.23</b>	<b>2,799.12</b>	<b>2,246.38</b>	<b>8,797.69</b>	<b>6,118.95</b>	<b>7,753.73</b>	
8	Exceptional items	-	-	-	-	-	-	
9	<b>Profit / Loss from ordinary activities before Tax (7 - 8)</b>	<b>2,659.23</b>	<b>2,799.12</b>	<b>2,246.38</b>	<b>8,797.69</b>	<b>6,118.95</b>	<b>7,753.73</b>	
10	Tax Expenses	357.54	411.53	190.28	1,691.04	708.73	548.69	
11	<b>Net Profit / Loss from ordinary activities after Tax (9 - 10)</b>	<b>2,301.69</b>	<b>2,387.59</b>	<b>2,056.09</b>	<b>7,106.64</b>	<b>5,410.21</b>	<b>7,205.04</b>	
12	Extraordinary Items (net of tax expenses Rs. .... / lacs)	-	-	-	-	-	-	
13	<b>Net Profit / Loss for period (11 - 12)</b>	<b>2,301.69</b>	<b>2,387.59</b>	<b>2,056.09</b>	<b>7,106.64</b>	<b>5,410.21</b>	<b>7,205.04</b>	
14	Share of Profit / (Loss) of associates	-	-	-	-	-	-	
15	Minority Interest	-	-	-	-	-	-	
16	<b>Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)</b>	<b>2,301.69</b>	<b>2,387.59</b>	<b>2,056.09</b>	<b>7,106.64</b>	<b>5,410.21</b>	<b>7,205.04</b>	
17	Paid up Equity Share Capital (Face value of the Share shall be indicated)	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38	
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	-	-	-	-	-	-	
19	Earnings per Share (before Extraordinary Items), (of Rs. .... / each) (not annualised)	(a) Basic	14.20	14.73	12.69	43.86	33.39	44.47
	(b) Diluted	14.20	14.73	12.69	43.86	33.39	44.47	

- The above Consolidated Unaudited Financial Results for the Quarter & Nine months ended DECEMBER 31, 2015 have been reviewed by Audit committee and taken on record by Board of Directors at their meeting held on 13<sup>th</sup> FEBRUARY 2016
- Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA, Inc., (iii) Klor Sehen Private Limited, (iv) Octantis Nobel Labs Private Limited, (v) Vivimed Labs (Alachur) Pvt Limited (vi) Finiso Pharma Pvt Limited and its step down subsidiaries (vii) vivimed specialty chemicals pvt ltd w/z, (viii) Vivimed Holdings Limited and its stepdown subsidiary Vivimed Labs Europe Limited (ix) Vivimed Labs Mauritius Limited and its stepdown subsidiaries (i) Vivimed Labs UK Limited, (ii) Vivimed Labs Spain, S.L, (iii) Union Quimica Farmaceutica S.A.U., Spain, (iv) Holiday International Limited UK & (v) Unifor Mexico S.A. de C.V.
- The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.
- As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
- Corresponding numbers of previous period / Year have been regrouped, wherever necessary.

Place : Hyderabad  
Date : 13.02.2016

For VIVIMED LABS LIMITED  
(SANTOSH VARALWARI)  
MANAGING DIRECTOR & CEO



VIVIMED LABS LIMITED

SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS AND CAPITAL EMPLOYED

₹ in Lacs

Particulars	3 Months Ended			Nine Months Ended		FY 15 31-03-2015 (Audited)
	31.12.2015 (Unaudited)	30.09.2015 (Unaudited)	31.12.2014 (Unaudited)	31.12.2015 (Unaudited)	31.12.2014 (Unaudited)	
<b>1. Segment Revenue</b> (net sales/income from each segment should be disclosed under this head)						
a. Speciality Chemicals Business	8,685.91	9,430.16	10,925.98	27,691.50	29,754.34	44,620.88
b. Pharma Business	24,305.20	24,272.64	23,444.91	72,155.28	72,634.06	93,389.04
<b>Total</b>	<b>32,991.12</b>	<b>33,702.81</b>	<b>34,370.89</b>	<b>99,846.77</b>	<b>102,388.40</b>	<b>138,009.92</b>
Less: Inter Segment Revenue						
<b>Net sales / Income from Operations</b>	<b>32,991.12</b>	<b>33,702.81</b>	<b>34,370.89</b>	<b>99,846.77</b>	<b>102,388.40</b>	<b>138,009.92</b>
<b>2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment</b>						
a. Speciality Chemicals Business	1,733.17	2,111.07	2,679.88	5,584.63	6,741.85	9,004.64
b. Pharma Business	2,847.78	2,567.67	1,503.73	8,918.89	5,310.79	6,652.77
<b>Total</b>	<b>4,580.95</b>	<b>4,678.74</b>	<b>4,183.61</b>	<b>14,503.52</b>	<b>12,052.64</b>	<b>15,657.41</b>
Less: 1. Interest	1,921.72	1,879.61	1,937.23	5,705.83	5,933.68	7,903.68
2. Other Un-allocable Expenditure						
3. Un-allocable Income						
<b>Total Profit Before Tax</b>	<b>2,659.23</b>	<b>2,799.12</b>	<b>2,246.38</b>	<b>8,797.69</b>	<b>6,118.95</b>	<b>7,753.73</b>
<b>3. Capital Employed</b>						
a. Speciality Chemicals Business	75,577.24	74,152.66	80,202.21	75,577.24	80,202.21	80,489.58
b. Pharma Business	67,345.35	66,437.84	62,269.98	67,345.35	62,269.98	68,208.23
<b>Total</b>	<b>142,922.59</b>	<b>140,590.51</b>	<b>142,472.19</b>	<b>142,922.59</b>	<b>142,472.19</b>	<b>148,697.80</b>

For VIVIMED LABS LIMITED

(SANTOSH KARALWAR)  
MANAGING DIRECTOR & CEO



Place : Hyderabad  
Date : 13.02.2016

VIVIMED LABS LIMITED  
STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2015

₹ IN LACS

Sl. No.	Particulars	Quarter Ended				Nine Months Ended		Previous Year ended 31.03.2015
		31.12.2015 (Unaudited)	30.09.2015 (Unaudited)	31.12.2014 (Unaudited)	31.12.2015 (Unaudited)	31.12.2014 (Unaudited)	(Audited)	
1	Income From Operations	8,005.34	8,009.12	10,527.52	23,985.78	30,373.54	43,014.81	
	(a) Net Sales / Income from Operations (Net of Excise Duty)	1.03	17.48	58.24	31.21	96.68	143.40	
	(b) Other Operating Income	8,006.38	8,026.61	10,585.76	24,016.99	30,470.22	43,158.21	
	Total Income From Operations (Net)	2,877.17	2,861.20	6,712.00	9,193.57	19,261.89	25,110.30	
	a. Cost of Raw Materials Consumed							
	b. Purchase of Stock in Trade	318.20	394.47	(2,048.74)	699.78	(5,518.20)	(5,319.45)	
	c. Changes in Inventories of Finished Goods, Work-in-Progress and Stock in Trade	619.67	604.85	624.01	1,754.29	2,003.62	2,788.34	
	d. Employee Benefit Expenses	447.53	412.75	663.71	1,344.79	1,563.49	2,056.04	
	e. Depreciation and Amortisation Expenses	1,993.65	1,973.72	2,404.14	5,720.31	6,775.33	9,863.94	
	f. Other Expenditure	6,256.23	6,246.99	8,355.12	18,712.75	24,086.13	34,499.17	
2	Total Expenses	1,750.15	1,779.62	2,230.64	5,304.24	6,384.09	8,659.04	
3	Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional Items (1 - 2)							
4	Other Income	1,750.15	1,779.62	2,230.64	5,304.24	6,384.09	8,659.04	
5	Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional Items (3 - 4)	1,410.94	1,502.14	1,714.03	4,405.90	4,633.55	6,233.53	
6	Finance Costs	339.21	277.48	516.61	898.33	1,750.54	2,425.51	
7	Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional Items (5 - 6)							
8	Exceptional Items	339.21	277.48	516.61	898.33	1,750.54	2,425.51	
9	Profit / Loss from ordinary activities before Tax (7 - 8)	67.84	50.43	103.32	165.69	416.79	531.99	
10	Tax Expenses	271.37	227.05	413.29	732.64	1,333.75	1,893.52	
11	Net Profit / Loss from ordinary activities after Tax (9 - 10)							
12	Extraordinary Items (net of tax expenses Rs...../Lacs)	271.37	227.05	413.29	732.64	1,333.75	1,893.52	
13	Net Profit / Loss for period (11 - 12)							
14	Share of Profit / (Loss) of associates							
15	Minority Interest	271.37	227.05	413.29	732.64	1,333.75	1,893.52	
16	Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38	
17	Reserve excluding Revolutation Reserves as per Balance Sheet of Previous Accounting Year							
18	Reserve excluding Revolutation Reserves as per Balance Sheet of Previous Accounting Year							
19	Earnings per Share (before Extraordinary Items) [of Rs...../- each] (not annualised)	1.67	1.40	2.55	4.52	8.23	11.69	
	(a) Basic	1.67	1.40	2.55	4.52	8.23	11.69	
	(b) Diluted							

- The above Standalone Unaudited Financial Results for the Quarter & Nine months ended DECEMBER 31, 2015 have been reviewed by Audit committee and token on record by Board of Directors at their meeting held on 13<sup>th</sup> FEBRUARY 2016
- The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.
- As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
- Corresponding numbers of previous period / year have been regrouped, wherever necessary.

Place : Hyderabad  
Date : 13.02.2016

For VIVIMED LABS LIMITED  
(SANTOSH VAPALWAR)  
MANAGING DIRECTOR & CEO



**VIVIMED LABS LIMITED**  
**SEGMENT-WISE STANDALONE FINANCIAL RESULTS AND CAPITAL EMPLOYED**

₹ in Lacs

Particulars	3 Months Ended			Nine Months Ended			FY 15
	31.12.2015 (Unaudited)	30.09.2015 (Unaudited)	31.12.2014 (Unaudited)	31.12.2015 (Unaudited)	31.12.2014 (Unaudited)	31-03-2015 (Audited)	
<b>1. Segment Revenue</b> (net sales/income from each segment should be disclosed under this head)							
a. Speciality Chemicals Business	6,052.85	5,914.68	8,060.31	18,033.57	24,074.34	34,941.15	
b. Pharma Business	1,952.49	2,094.44	2,467.21	5,952.21	6,299.20	8,073.66	
<b>Total</b>	<b>8,005.34</b>	<b>8,009.12</b>	<b>10,527.52</b>	<b>23,985.78</b>	<b>30,373.54</b>	<b>43,014.81</b>	
Less, Inter Segment Revenue							
<b>Net sales / Income from Operations</b>	<b>8,005.34</b>	<b>8,009.12</b>	<b>10,527.52</b>	<b>23,985.78</b>	<b>30,373.54</b>	<b>43,014.81</b>	
<b>2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment</b>							
a. Speciality Chemicals Business	1,513.78	1,583.55	1,873.78	4,734.23	5,270.86	7,271.32	
b. Pharma Business	236.37	196.07	356.86	570.01	1,113.23	1,387.72	
<b>Total</b>	<b>1,750.15</b>	<b>1,779.62</b>	<b>2,230.64</b>	<b>5,304.24</b>	<b>6,384.09</b>	<b>8,659.04</b>	
Less: 1. Interest	1,410.94	1,502.14	1,714.03	4,405.90	4,633.55	6,233.53	
2. Other Un-allocable Expenditure							
3. Un-allocable Income							
<b>Total Profit Before Tax</b>	<b>339.21</b>	<b>277.48</b>	<b>516.61</b>	<b>898.33</b>	<b>1,750.54</b>	<b>2,425.51</b>	
<b>3. Capital Employed</b>							
a. Speciality Chemicals Business	79,807.08	79,173.69	77,390.74	79,807.08	77,390.74	81,955.60	
b. Pharma Business	32,566.73	32,244.29	29,567.82	32,566.73	29,567.82	31,968.95	
<b>Total</b>	<b>112,373.81</b>	<b>111,417.98</b>	<b>106,958.56</b>	<b>112,373.81</b>	<b>106,958.56</b>	<b>113,924.55</b>	

Place : Hyderabad  
 Date : 13.02.2016

For VIVIMED LABS LIMITED  
 (SANTOSH VARALWAR)  
 MANAGING DIRECTOR & CEO





**P. MURALI & CO.,**

CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com

TO  
The Board of Directors  
Vivimed Labs Limited  
Hyderabad.

Limited Review Report for the quarter ended 31<sup>st</sup> December, 2015

We have reviewed the accompanying statement of unaudited financial results of Vivimed Labs Limited for the period ended 31<sup>st</sup> December 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P.Murali & Co.  
Chartered Accountants



M V Joshi  
Partner  
M.No. 024784

Place: Hyderabad  
Date: 13<sup>th</sup> February 2016